Related Experiment Video

Updated: May 20, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Hepatitis C variability, patterns of resistance, and impact on therapy

Cristina Simona Strahotin1, Michael Babich

  • 1Division of Gastroenterology, West Penn Allegheny Health System, 1307 Federal Street, Ste 301, Pittsburgh, PA 15212, USA.

Advances in Virology
|August 2, 2012
PubMed

Insights

Hepatitis C (HCV) treatment advances include new direct antiviral agents, improving cure rates but facing resistance. Future strategies may involve novel drug classes or a vaccine for HCV eradication.

Area of Science:

  • Hepatology and Virology
  • Infectious Diseases
  • Drug Development and Resistance

Background:

  • Hepatitis C virus (HCV) is a primary cause of chronic liver disease, cirrhosis, and liver cancer, frequently necessitating liver transplantation.
  • Despite declining incidence, an aging infected population suggests a growing HCV burden.
  • HCV exhibits resistance to antiviral therapies, highlighting incomplete knowledge and treatment challenges.

Purpose of the Study:

  • To review mechanisms of HCV drug resistance.
  • To analyze traditional and current standard-of-care treatments for Hepatitis C.
  • To explore future therapeutic directions and the potential for HCV vaccine development.

Main Methods:

  • Literature review of HCV resistance mechanisms.
  • Analysis of traditional treatments (PEG-IFN-α and ribavirin).
  • Evaluation of new direct-acting antiviral agents (telaprevir, boceprevir) in triple therapy regimens.

Main Results:

  • New triple therapy regimens combining PEG-IFN-α, ribavirin, and direct antivirals show increased viral cure rates.
  • Treatment failure remains a possibility despite advancements.
  • Emerging drug classes like nucleoside/nucleotide analogues and polymerase inhibitors show promise.

Conclusions:

  • Current HCV treatment has advanced with triple therapy, but challenges like resistance persist.
  • Future HCV treatment may mirror HIV therapy, utilizing novel drug classes.
  • Development of an HCV vaccine is crucial for cost-effective disease eradication.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Isolation of Fidelity Variants of RNA Viruses and Characterization of Virus Mutation Frequency18:10

Isolation of Fidelity Variants of RNA Viruses and Characterization of Virus Mutation Frequency

Published on: June 16, 2011

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...